Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Educating Your Patients About Daratumumab

Conference Correspondent  - Hematologic Cancers, Conference Correspondent, ASH
Leslie Lauersdorf, ARNP
Leslie Lauersdorf insist that it's vital to inform your patients about what's involved in beginning daratumumab treatments, especially because of the lengthy chair time.
Related Items
November 4, 2019 — Oncology News & Updates
Web Exclusives published on November 5, 2019 in Financial Toxicity, Head and Neck Cancer, Hematologic Cancers, In the News, Leukemia
Checkpoint Inhibition Consolidation Therapy Promising in High-Risk Hematologic Malignancies
Charles Bankhead
JHOP - March 2019 Vol 9, No 1 published on March 13, 2019 in ASH
MURANO: Venetoclax-Rituximab at Fixed Duration Beats Chemo­immunotherapy in Relapsed/Refractory CLL
Phoebe Starr
JHOP - March 2019 Vol 9, No 1 published on March 13, 2019 in ASH
Researchers Identify First Mutation to Explain Resistance to Venetoclax
Phoebe Starr
JHOP - March 2019 Vol 9, No 1 published on March 13, 2019 in ASH
Checkpoint Inhibitor a New Approach to Jump-Start a Waning Response to CAR T-Cell Therapy
Phoebe Starr
JHOP - March 2019 Vol 9, No 1 published on March 13, 2019 in Immunotherapy, ASH
Durable Responses to CAR T-Cell Therapy in B-Cell Lymphomas
Phoebe Starr
JHOP - March 2019 Vol 9, No 1 published on March 13, 2019 in Lymphoma, ASH
First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with CLL
Wayne Kuznar
JHOP - March 2019 Vol 9, No 1 published on March 13, 2019 in Leukemia, ASH
Impact of Pharmacist-Driven Educational Intervention on Documentation of Bowel Function Assessment in Patients with Cancer Who Are Using Opioids
Kimberly N. Flynn, PharmD, BCPS, Celestine Gochett, PhD, AOCNS
JHOP - March 2018 Vol 8, No 1 published on March 1, 2018 in ASH, Original Research
Nivolumab plus Azacitidine Shows Encouraging Activity in R/R AML or as Frontline Therapy in Elderly Patients with AML
JHOP - March 2018 Vol 8, No 1 published on March 1, 2018 in ASH
Safety and Tolerability of Midostaurin from Expanded Treatment Protocol in Patients with FLT3 Mutation–Positive, Newly Diagnosed AML
JHOP - March 2018 Vol 8, No 1 published on March 1, 2018 in ASH
Last modified: December 5, 2017